Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BIRB 796 BS with and without Pantoprazole
NCT02209831Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2001
- Primary completion
- Jan 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of doramapimod in Crohn's disease, psoriasis and rheumatoid arthritis (RA) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the plasma concentration versus time curve from time 0 extrapolated to infinity up to 36 hours. Started Nov 2001; status: completed.
02
Drugs
doramapimod
03
Conditions
Crohn's diseasepsoriasisrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02209831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209831.